| pubmed-article:8174049 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8174049 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8174049 | lifeskim:mentions | umls-concept:C0149911 | lld:lifeskim |
| pubmed-article:8174049 | lifeskim:mentions | umls-concept:C0574032 | lld:lifeskim |
| pubmed-article:8174049 | lifeskim:mentions | umls-concept:C0037507 | lld:lifeskim |
| pubmed-article:8174049 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:8174049 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:8174049 | pubmed:dateCreated | 1994-6-7 | lld:pubmed |
| pubmed-article:8174049 | pubmed:abstractText | Hypercalcemia is a serious and common complication of malignancy. Etidronate, a known inhibitor of osteoclastic bone resorption, is approved in the therapy of hypercalcemia of malignancy (HCM) at a dose of 7.5 mg/kg/day infused during a period of 2-4 hours on 3 consecutive days. A multicenter study was conducted to evaluate the safety and efficacy of a single 24-hour infusion of etidronate disodium in patients with HCM. | lld:pubmed |
| pubmed-article:8174049 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8174049 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8174049 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8174049 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8174049 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8174049 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8174049 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8174049 | pubmed:month | May | lld:pubmed |
| pubmed-article:8174049 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:8174049 | pubmed:author | pubmed-author:ChapmanR ARA | lld:pubmed |
| pubmed-article:8174049 | pubmed:author | pubmed-author:ChangA YAY | lld:pubmed |
| pubmed-article:8174049 | pubmed:author | pubmed-author:RudeR KRK | lld:pubmed |
| pubmed-article:8174049 | pubmed:author | pubmed-author:HoffJ VJV | lld:pubmed |
| pubmed-article:8174049 | pubmed:author | pubmed-author:PritchardJ... | lld:pubmed |
| pubmed-article:8174049 | pubmed:author | pubmed-author:BelaniC PCP | lld:pubmed |
| pubmed-article:8174049 | pubmed:author | pubmed-author:FloresJ FJF | lld:pubmed |
| pubmed-article:8174049 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8174049 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8174049 | pubmed:volume | 73 | lld:pubmed |
| pubmed-article:8174049 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8174049 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8174049 | pubmed:pagination | 2527-34 | lld:pubmed |
| pubmed-article:8174049 | pubmed:dateRevised | 2010-3-24 | lld:pubmed |
| pubmed-article:8174049 | pubmed:meshHeading | pubmed-meshheading:8174049-... | lld:pubmed |
| pubmed-article:8174049 | pubmed:meshHeading | pubmed-meshheading:8174049-... | lld:pubmed |
| pubmed-article:8174049 | pubmed:meshHeading | pubmed-meshheading:8174049-... | lld:pubmed |
| pubmed-article:8174049 | pubmed:meshHeading | pubmed-meshheading:8174049-... | lld:pubmed |
| pubmed-article:8174049 | pubmed:meshHeading | pubmed-meshheading:8174049-... | lld:pubmed |
| pubmed-article:8174049 | pubmed:meshHeading | pubmed-meshheading:8174049-... | lld:pubmed |
| pubmed-article:8174049 | pubmed:meshHeading | pubmed-meshheading:8174049-... | lld:pubmed |
| pubmed-article:8174049 | pubmed:meshHeading | pubmed-meshheading:8174049-... | lld:pubmed |
| pubmed-article:8174049 | pubmed:meshHeading | pubmed-meshheading:8174049-... | lld:pubmed |
| pubmed-article:8174049 | pubmed:meshHeading | pubmed-meshheading:8174049-... | lld:pubmed |
| pubmed-article:8174049 | pubmed:meshHeading | pubmed-meshheading:8174049-... | lld:pubmed |
| pubmed-article:8174049 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8174049 | pubmed:articleTitle | Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. | lld:pubmed |
| pubmed-article:8174049 | pubmed:affiliation | USC School of Medicine, Los Angeles. | lld:pubmed |
| pubmed-article:8174049 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8174049 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8174049 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8174049 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:8174049 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:8174049 | pubmed:publicationType | Multicenter Study | lld:pubmed |
